| TA36 |
Rheumatoid arthritis - etanercept and infliximab (TA36) (replaced by TA130 and TA195) |
|
-
-
The clinical effectiveness and cost effectiveness of etanercept and infliximab for rheumatoid arthritis and juvenile poly-articular idiopathic arthritis.
This guidance has been replaced by TA130 Rheumatoid arthritis - adalimumab, etanercept and infliximab and TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
-
Other information
How this guidance was produced
Background information
- None found
This page was last updated: 20 December 2011
-
-
Guidance formats
-
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
